Pneumonitis related to docetaxel: Case report and review of the literature

In Vivo

Volumn 23, Issue 4, 2009, Pages 635-638

  Alsamarai, Susan ^a   Charpidou, Andriani G ^b   Matthay, Richard A ^a   Confeld, Daniel ^a   Syrigos, Kostas N ^a,b,c   Saif, Muhammad W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Breast cancer; Docetaxel; Gastric cancer; Lung cancer; Pneumonitis

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; MOXIFLOXACIN; PREDNISONE;

AGED; ANAMNESIS; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN TISSUE; LABORATORY TEST; LAPAROTOMY; MALE; OPEN LUNG BIOPSY; PNEUMONIA; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

EID: 67650935918     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Semb KA, Aamdal S and Oian P: Capillary protein leak syndrome appears to explain fluid retention in cancer patient who receive docetaxel treatment. J Clin Oncol 16: 3426-3432, 1998.
2. Charpidou AG, Gkiozos I, Tsimpoukis S, Apostolaki D, Dialana KD, Karapanagiotou E and Syrigos KN: Therapy-induced toxicity of the lungs: an overview. Anticancer Res 29: 631-640, 2009.
3. Dimopoulou I, Bamias A, Lyberopoulos P and Dimopoulos MA: Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17(3): 372-379, 2006. (Pubitemid 43329572)
4. Engels FK, R Mathot and J Verweij: Alternative drug formulations of docetaxel: a review. Anticancer Drugs 18(2): 95-103, 2007.
5. Piccart MJ, Klijn Jand Paridaens R: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of the randomized study of the European Organazation for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15: 3149-3155, 1997.
6. Khan A, McNally D, Tutschka PJ and Bilgrami S: Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 31: 1471-1474, 1997. (Pubitemid 28013175)
7. Ramanathan RK, Reddy VV, Holbert JM and Belani CP: Pulmonary infiltrates following administration of paclitaxel. Chest 110: 289-292, 1996.
8. Read WL, Mortimer JE and Picus J: Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94(3): 847-853, 2002. (Pubitemid 34132316)
9. Mileshkin L, Prince HM, Rischin D and Zimet A: Severe interstitial pneumonitis following high-dose cyclosphosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplantation 27(5): 559-563, 2001. (Pubitemid 32266510)
10. Merad M, Le Cesne A, Baldeyrou P, Mesurolle B and Le Chevalier T: Docetaxel and interstitial pulmonary injury. Ann Oncol 8: 191-194, 1997.
11. Dunsford ML, Mead GM, Baterman AC, Cook T and Tung K: Severe pulmonary toxicity in patients treated with combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 10: 943-947, 1999. (Pubitemid 29424574)
12. Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM and Vokes EE: Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16: 159-164, 1998.